ReviewEmerging infectious diseases2010
Decrease in shigellosis-related deaths without Shigella spp.-specific interventions, Asia.
Review in Emerging infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Estimating diarrheal illness and deaths attributable to Shigellae and enterotoxigenic Escherichia coli among older children, adolescents, and adults in South Asia and Africa.PLoS neglected tropical diseases · 2014Pooled it
- Global causes of diarrheal disease mortality in children <5 years of age: a systematic review.PloS one · 2013Pooled it
- Causative species and serotypes of shigellosis in mainland China: systematic review and meta-analysis.PloS one · 2012Pooled it
- Trial
- Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.Clinical and vaccine immunology : CVI · 2016Trial
- Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial.BMC infectious diseases · 2012Trial
- Genome-based re-evaluation of the ECA75F sequence and development of a dual-probe real-time PCR assay for differentiatingMicrobiology spectrum · 2026Article
- Article
- Identification, antimicrobial susceptibility test, and pathogenicity analysis ofFrontiers in microbiology · 2026Article
- Utilizing the effectiveness of phage cocktail to combat Shigella and Salmonella infections and their polymicrobial biofilm control activity.BMC microbiology · 2025Article
- Shigella sonnei: epidemiology, evolution, pathogenesis, resistance and host interactions.Nature reviews. Microbiology · 2025Review
- Safety and Tolerability of ShigActive™, aAntibiotics (Basel, Switzerland) · 2024Article
- Shigella-Controlled Human Infection Models: Current and Future Perspectives.Current topics in microbiology and immunology · 2024Review
- Roles of host SUMOylation in bacterial pathogenesis.Infection and immunity · 2023Review
- Differential invasiveness & expression of antimicrobial peptides inThe Indian journal of medical research · 2023Article
- The Fascinating Cross-Paths of Pathogenic Bacteria, Human and Animal Faecal Sources in Water-Stressed Communities of Vhembe District, South Africa.Pathogens (Basel, Switzerland) · 2023Article
- Toward aInternational journal of molecular sciences · 2023Review
- Evolutionary and genomic insights into the long-term colonization ofEmerging microbes & infections · 2022Article
- A Shigella sonnei clone with extensive drug resistance associated with waterborne outbreaks in China.Nature communications · 2022Article
- High frequency of antimicrobial resistance and virulence gene in Shigella species isolated from pediatric patients in an Iranian Referral Hospital.Acta bio-medica : Atenei Parmensis · 2022Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 1999, a review of the literature for 1966-1997 suggested that ≈1.1 million persons die annually of shigellosis, including ≈880,000 in Asia. Our recent review of the literature for 1990-2009 indicates that ≈125 million shigellosis cases occur annually in Asia, of which ≈14,000 are fatal. This estimate for illnesses is similar to the earlier estimate, but the number of deaths is 98% lower; that is, the lower estimate of deaths is associated with markedly reduced case-fatality rates rather than fewer cases. Shigella spp.-related deaths decreased substantially during a period without Shigella spp.-specific interventions. We speculate that nonspecific interventions, e.g., measles vaccination, vitamin A supplementation, and improved nutrition, may have led to the reduced number of shigellosis-related deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.